Polycystic ovary syndrome: A management update

Australian Family Physician

Volumn 34, Issue 3, 2005, Pages 127-133

  Costello, Michael F ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b IVFAustralia   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; METFORMIN; ORAL CONTRACEPTIVE AGENT;

ECHOGRAPHY; FEMALE; GENERAL PRACTICE; GLUCOSE INTOLERANCE; HUMAN; INFERTILITY; MENSTRUATION DISORDER; METHODOLOGY; OBESITY; OVARY; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PREGNANCY; REVIEW; RISK FACTOR;

CONTRACEPTIVES, ORAL; FAMILY PRACTICE; FEMALE; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; INFERTILITY; MENSTRUATION DISTURBANCES; METFORMIN; OBESITY; OVARY; POLYCYSTIC OVARY SYNDROME; PREGNANCY; RISK FACTORS;

EID: 17244375689     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078-82.
2. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006-11.
3. Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected caucasian women from Spain. J Clin Endocrinol Metab 2000;85:2434-8.
4. Homburg R. Polycystic ovary syndrome: from gynaecological curiosity to multisystem endocrinopathy. Hum Reprod 1996;11:29-39.
5. Balen A, Michelmore K. What is polycystic ovary syndrome? Are national views important?. Hum Reprod 2002;17:2219-27.
6. Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fert Steril 2002;77:1095-105.
7. Wild RA. Long term health consequences of PCOS. Hum Reprod Update 2002;8:231-41.
8. Wild RA. Polycystic ovary syndrome: a risk for coronary artery disease?. Am J Obstet Gynecol 2002;186:35-43.
9. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-74.
10. Conway GS, Jacobs HS, Holly JMP, Wass JA. Effects of luteinising hormone, insulin, insulin-like growth factor-1 and insulin-like growth factor small binding protein-1 in the polycystic ovary syndrome. Clin Endocrinol 1990;33:593-603.
11. Dunaif A. Molecular mechanisms of insulin resistance in the polycystic ovary syndrome. Semin Reprod Endrocrinol 1994;12:15-20.
12. Azziz R, Kashar-Miller MD. Family history as a risk factor for the polycystic ovary syndrome. J Pediat Endocrinol Metabol 2000;13:1303-6.
13. Legro RS, Strauss JF. Molecular progress in infertility: polycystic ovary syndrome. Fertil Steril 2002;78:569-76.
14. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181-91.
15. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-7.
16. Poulson DW, Adams J, Wadswurth J. Polycystic ovaries: a common finding in normal women. Lancet 1988;1:870-2.
17. Hassan MA, Killick SR. Ultrasound diagnosis of polycystic ovaries in women who have no symptoms of polycystic ovary syndrome is not associated with subfecundity or subfertility. Fertil Steril 2003;80:966-75.
18. Engmann L, Maconochie N, Sladkevicius P, Bekir J, Campbell S, Tan SL. The outcome of in-vitro fertilisation treatment in women with sonographic evidence of polycystic ovarian morphology. Hum Reprod 1999;14:167-71.
19. Hardiman P, Pillay OS, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet 2003;361:1810-2.
20. Balen A. Polycystic ovary syndrome and cancer. Hum Reprod Update 2001;7:522-5.
21. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Roberts KA, Nestler JE. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:524-9.
22. Regan L, Braude PR, Trembath PL. Influence of past reproductive performance on risk of spontaneous abortion. BMJ 1989;299:541-5.
23. Rai R, Backos M, Rushworth F, Regan L. Polycystic ovaries and recurrent miscarriage: a reappraisal. Hum Reprod 2000;15:612-5.
24. Nardo LG, Rai R, Backos M, El-Gaddal S, Regan L. High serum luteinizing hormone and testosterone concentrations do not predict pregnancy outcome in women with recurrent miscarriage. Fertil Steril 2002;77:348-52.
25. Wang JX, Davies MJ, Norman RJ. Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Hum Reprod 2001;16:2606-9.
26. Radon PA, McMahon MJ, Meyer WR. Impaired glucose tolerance in pregnant women with polycystic ovary syndrome. Obstet Gynecol 1999;942:194-7.
27. Bjercke S, Dale PO, Tanbo T, Storeng R, Ertzeid G, Abyholm T. Impact of insulin resistance on pregnancy complications and outcome in women with polycystic ovary syndrome. Gynecol Obstet Invest 2002;54:94-8.
28. Ferrimann D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-7.
29. American Diabetes Association (ADA). Screening for diabetes. Diabetes Care 2002;25:S21-4.
30. National Health and Medical Research Council. National evidence based guidelines for the management of type 2 diabetes mellitus, 2001. Available at: www.adea.com.au/resources/nhmrct2.html.
31. Legro RS. Diabetes prevalence and risk factors in polycystic ovary syndrome. Obstet Gynecol Clin Nth America 2001;28:99-109.
32. Moran L, Norman RJ. Understanding and managing disturbances in insulin metabolism and body weight in women with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004;18:719-36.
33. Lord JM, Flight IHK, Norman RJ. Insulin sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiroinositol) for polycystic ovary syndrome (Cochrane Review). In: The Cochrane Library, Issue 2. Chichester, UK: John Wiley & Sons, Ltd, 2004.
34. Norman RJ, Davies MJ, Lord J, et al. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 2002;13:251-7.
35. Clarke AM, Ledger W, Galletly C, Tomlinson L, Blaney F, Wang X, Norman RJ. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 1995;10:2705-12.
36. Costello MF, Eden JA. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril 2003;79:1-13.
37. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
38. Diamanti-Kandarakis E, Baillargeon, JP, Iuorno MJ, Jakubowicz DJ, Nestler JE. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrin Metab 2003;88:1927-32.
39. Glueck CJ, Wang P, Kobayashi S, Phillips H, Sieve-Smith L. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 2002;77:520-5.
40. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.